© 2016
“DrugDiscovery @LPBI Group”
is a Start Up in
Health/Life Sciences in MA
“DrugDiscovery @LPBI Group” combines expertise from three sources:
a. Leadership of SBH Sciences, Inc, CEO, Raphael Nir, PhD
Co-Founder: “DrugDiscovery @LPBI Group”, Expertise for Startup evolution:
- Management: Team building, Funding, Decision Making
- All Aspects of R&D Management
- Conceptual Leadership
b. Leadership of LPBI Group, Founder, Aviva Lev-Ari, PhD, RN
Co-Founder: “DrugDiscovery @LPBI Group”, Expertise for Startup evolution:
- Management: Team building, Funding, Administration
- R&D Management: Concept Design Strategy, Combination Drug Therapy
Co-Founder “DrugDiscovery @LPBI Group”, Stephen J. Williams, PhD, Expertise for Startup evolution:
- Strategic Decision Making
- All Aspects of Research
- Conceptual Leadership in Drug Formulation
- 3D BioPrinting: Drug Dosing and Printing
c. Team members of LPBI Group, M3DP Venture (Subsidiary #3)
c.1 Member of Technical Staff: Tilda Barliya, PhD, Expertise for Startup evolution:
- All Aspects of Research
- Conceptual Leadership in Drug Formulation, nano beads, oncology, genomics
c.2 Member of Technical Staff: Irina Robu, PhD, Expertise for Startup evolution:
- All Aspects of Research related to Material Science, Tissue Engineering
- Conceptual Leadership in Drug-Device design for drug delivery, Smart Polymers
c.3 Member of Technical Staff: David Orchard-Webb, Expertise for Startup evolution
- cancer biology, pancreatic disorders, biologics, molecular and cellular biology and immunology
- Conceptual Leadership in Novel mechanism of action and combination therapy of Biologics
We are adding Scientists to our Team
SBH Sciences, Inc. & LPBI Group’s M3DP, Subsidiary #3
Thrusts of “DrugDiscovery @LPBI Group” include:
- Drug Discovery with 3D BioPrinting
- Drug Delivery System – One solution for many agents for many indications
- Stem Cell Reprogramming & Gene Therapy
- Gene Editing for Gene Therapies with 3D BioPrinting
- JVIP – TEAM PRESENTATIONS 1/4/2016 – 3/31/2016
Drug Development – Three Indications
- Diabetes – A Combination Drug Therapy to induce Insulin Production by Pancreatic Beta Cells (PPAR-gamma, Leptin, ..)
- Inflammatory Disorders: Inflammatory Bowel Diseases (IBD) – Crohn’s and Ulcerative Colitis (UC) and Others
- Anti-Cancer Drug Discovery @ LPBI Group’s Research Biotech Businesses
Methodology and Processes
- CRISPR – genecards.org, UCSC, NM/OK, Caribou BioSciences
- PROTOCOL for LPBI Group’s Recruiting Strategy for R&D Scientists I,II,III and R&D Project Managers for Drug Discovery: Three Indications Considered
- PROTOCOL for Drug Screening of 3rd Party Intellectual Property Presented for Funding Representation
The Team
Team Profile: DrugDiscovery @LPBI Group – A BioTech Start Up submitted for Funding Competition to MassChallenge Boston 2016 Accelerator
https://accelerate.masschallenge.org/startup/11021/team/
We are Applicants for MassChallenge Boston 2016 Accelerator
https://accelerate.masschallenge.org/startup/11021/team/
From: MassChallenge <apply@masschallenge.org>
Date: Monday, March 28, 2016 at 1:11 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: MassChallenge <apply@masschallenge.org>
Subject: Your MassChallenge 2016 Jun-Oct Program Cycle Application for DrugDiscovery@LPBI Group has been Submitted
Hi Aviva,
Thank you for submitting your application for MassChallenge Boston 2016 Accelerator for your startup, DrugDiscovery@LPBI Group. It has been received and will be reviewed by MassChallenge judges.
Best,
The MassChallenge Team
++
From: MassChallenge <contact@masschallenge.org>
Reply-To: <contact@masschallenge.org>
Date: Saturday, April 2, 2016 at 3:17 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: MC Update – Applications Close
Boston, Jerusalem Lausanne – Timeline
February 9: Applications Open. Entrepreneurs apply online to MassChallenge 2016 programs.
March 2 (NOON EST): Early bird application deadline. Apply early and receive discounted application fee ($49).
April 1 (NOON EDT): Regular application deadline. This is the last date to submit applications for the 2016 accelerator programs. Regular application fee applies ($99).
March 29 – April 22: Round 1 Judging: Expert judges assess online applications and provide feedback to entrants. Each application receives scoring and feedback from multiple judges.
May 4 – May 11: Round 2 Judging: Semi-finalist startups deliver 20-minute pitches to panels of judges in Boston, Lausanne, or Jerusalem. Live Q&A followed up by written scoring and feedback.
May 19: Finalist Announcement. The most promising startups are invited to participate in the MassChallenge 2016 accelerator programs as finalists.
June 20 – October 14: Accelerator Program. Access to world-class mentorship, training, office space, funding, marketing, media and other resources.
September 27 – September 29: Pre-final Judging: Finalists pitch to panels of judges highlighting their progress during the accelerator.
October 13 & 14: Final Judging. The top 26 startups pitch to high profile judges, who determine cash awards.
October 27: Israel Awards Ceremony.
November 2: Boston Awards Ceremony.
Click to Browse the 2016 Startup Applicants
About LPBI Group
Lines of Business #1,2,3,4,5 are in
- eScientific Digital Media & IP Asset Management (Subsidiary #1 and #4)
and in
- Funding Early Stage (Subsidiary #2)
About “DrugDiscovery @LPBI Group”
“DrugDiscovery @LPBI Group” is assuming the activities of Subsidiary #5: SBH Sciences, Inc and LPBI Group’s Team in Biotech 3D BioPrinting R&D – Drug Development (Subsidiary #3: M3DP: Team in Drug Development and Team in Medical Devices)
We are in Research Biotech Businesses
-
Subsidiary 3: R&D in 3D BioPrinting
Line-of-Business #6: “3D BioPrinting: Drugs” & “3DBioPrinting: Medical Devices”
Tissue Engineering, Gene Therapy: Stem Cells & Gene Editing, Medical Devices: Product Concepts
&
-
Subsidiary 5: Pharmaceutical R&D: Drug Discovery and Drug-Devices Development
Line-of-Business #7:
Line-of-Business #8:
2012pharmaceutical
sjwilliamspa